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ECONOMICAL EVALUATION OF DIFFERENT FORMS OF BETAHISTINE 
IN PATIENTS WITH VERTIGO
Vorobyev PA1, Lesnicheva MV2, Morozova SV3, Suleymanov SS4, Sarvilina IV2, Kupayev VI2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 
2Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Moscow, 
Russia, 3I.M. Sechenov Moscow Medical Academy, Moscow, Moscow, Russia, 4Russian 
Society for Pharmacoeconomics and Outcomes Research, Khabarovsk, Khabarovsk, Russia
OBJECTIVES: to perform economic evaluation of three forms of betahistine in 
patients with vertigo. METHODS: an open-labeled prospective multicenter random-
ized study was performed in 14 out-patient clinics of Russia. The duration of a study 
was 30 days. Patients with vertigo were treated with three forms of betahistine 
(Betaserc, Betaver, Vestibo) in combination with any other medications to the discre-
tion of investigator. The effectiveness criteria were proportion of patients with absence 
of moderate and severe functional disorders (according to International Classiﬁcation 
of Functioning, Disability and Health) and increase of patients’ quality of life rate 
compared to the initial one (according to EQ-5D questionnaire). Cost-effectiveness 
and cost-utility ratios were calculated. RESULTS: Betaver group included 70 (33.2%) 
patients, Betaserc group—71 (33.6%) patients, and Vestibo group—70 (33.2%) 
patients with moderate vertigo. All patients initially had moderate and severe func-
tional disorders. The proportion of patients without absence of moderate and severe 
functional disorders up to the end of a study was 54% in Betaver group, 57% in 
Vestibo group and 69% in Betaserc group. The average difference between initial 
quality of life rate and the quality of life after the treatment was 19.53, 19.62 and 
22.79 (Betaver, Vestibo and Betaserc groups accordingly). Cost of treatment was 
nearly similar in all groups. The cost-effectiveness ratio according to the criteria “the 
proportion of patients with absence of moderate and severe functional disorders” was 
minimal in Betaserc group (8,088.57) compared to Betaver (10,358.17) and Vestibo 
(8,955.49) groups. The cost-utility ratio according to the criteria “the increase of 
patients’ quality of life rate compared to the initial one” was also minimal in Betaserc 
group (244.89) compared to Betaver (286.4) and Vestibo (260.17) groups. CONCLU-
SIONS: Betaserc seems to be more clinically and economically effective betahistine 
compared to another two medications in treatment of patients with vertigo.
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COST SAVING OPPORTUNITY OF POTENTIAL PHARMACIST-
INITIATED IV-TO-PO LEVETIRACETAM SWITCHES: A PREDICTION 
MODEL BASED ON REAL-WORLD DATA
Yeh JY, Garrity LC, Ahrens CL
Cleveland Clinic, Cleveland, OH, USA
OBJECTIVES: Opportunity exists for certain hospitalized patients to appropriately 
receive oral (PO) levetiracetam given its bioavailability of 100%. Use of intravenous 
(IV) levetiracetam at our institution had increased and was associated with signiﬁcant 
annual cost. This study aimed to evaluate the use of IV levetiracetam, to identify a 
cost saving opportunity and to project cost savings of potential pharmacist-initiated 
IV-to-PO levetiracetam switches. The goal was to provide information regarding 
medication utilization and cost saving opportunities for hospital administration to 
make informed formulary decisions. METHODS: A retrospective medical chart review 
on 100 randomly selected adult patients receiving at least two doses of IV levetirace-
tam during hospital stays between July 1, 2008 and November 30, 2008 was con-
ducted. Pre-deﬁned eligibility of IV-to-PO levetiracetam switches, costs, doses and 
frequencies were obtained for each patient-day. Only levetiracetam costs were consid-
ered and presented as 2008 average wholesale prices without further adjustments. 
Monte Carlo simulation models were created to predict cost savings, and model 
inputs, parameters and plausible ranges were determined based on real-world data. 
Three scenarios were hypothesized where switches could have been made with “no 
delay,” “12-hour delay” or “24-hour delay” of pharmacist interventions upon iden-
tiﬁcation of eligibility. Probabilistic sensitivity analysis was performed (2,500 trials) 
for each scenario. RESULTS: Among 729 patient-days (from 99 subjects with one 
subject excluded as an outlier), 6.6% made IV-to-PO levetiracetam switches and 
additional 66% were eligible for such switch. With a conservative scenario of 24-hour 
delay, potential cost savings were estimated as follows: mean $512 (SD $714) per 
patient or $69.6 (SD $0.4) per patient-day; median $302 (95% CI $20-$1,661) per 
patient. Of 2,500 estimates, 19.6% could have potential savings of $100–200 
per patient, followed by $0-$100 (15.5%), $200-$300 (14.6%) and $300-$400 
(9.6%). CONCLUSIONS: Pharmacists have potential cost saving opportunities by 
identiﬁcation of eligible IV-to-PO levetiracetam switches.
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ECONOMIC EVALUATION OF THE IMPACT OF MEMANTINE ON  
TIME TO NURSING HOME ADMISSION IN THE TREATMENT OF 
ALZHEIMER’S DISEASE
Lachaine J1, Beauchemin C1, Legault M2, Le Lay A3
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada Inc., Montreal, QC, 
Canada, 3Lundbeck SAS, Paris, France
OBJECTIVES: An observational study recently showed that combining memantine 
with a cholinesterase inhibitor (ChEI) treatment signiﬁcantly delayed admission to a 
nursing home in patients with Alzheimer’s disease. The objective of this analysis was 
to evaluate the economic impact of the concomitant use of memantine and ChEI on 
time to institutionalization in a Canadian population. METHODS: A cost-utility 
analysis using a Markov model over a 7 years time horizon was performed according 
to a public third party perspective and a societal perspective. The Markov model 
includes the following states: non-institutionalized, institutionalized, and deceased. 
Transition probabilities for institutionalisation were taken from the study by Lopez 
et al., while transition probabilities for death were taken from Canadian survival tables 
and adjusted for mortality rates speciﬁc to Alzheimer’s disease. For the publicly funded 
health care system perspective, costs of medication (ChEI and ChEI + memantine) as 
well as the costs of care provided in the community and in nursing homes were 
considered. For the societal perspective, costs of direct care and supervision provided 
by caregivers were added. RESULTS: From both a societal and a publicly funded 
health care system perspective, the concomitant use of a ChEI and memantine is a 
dominant strategy over the use of a ChEI alone. Thus, the costs associated with the 
use of memantine in combination with a ChEI are lower than those associated with 
the use of a ChEI alone, and the number of Quality-adjusted-life-years (QALYs) 
obtained with a ChEI plus memantine is higher than the number of QALYs obtained 
with a ChEI alone. CONCLUSIONS: The results of this economic evaluation indicate 
that the use of memantine combined with a ChEI to treat Alzheimer’s disease is a 
cost-effective alternative compared to the use of a ChEI alone, both from a health care 
and societal perspective.
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HEALTH STATUS, RESOURCE UTILIZATION, AND WORK 
PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH EPILEPSY: A 
PROPENSITY SCORE ANALYSIS OF NATIONAL SURVEY DATA
Abouzaid S1, DiBonaventura MD2, Forlenza JB1, Durkin MB1
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Titusville, NJ, USA, 2KantarHealth, New York, 
NY, USA
OBJECTIVES: Compare health status, resource utilization, and work productivity 
between caregivers for an adult with epilepsy and a control group of non-caregivers. 
METHODS: Respondents to the 2009 U.S. National Health and Wellness Survey 
(NHWS), a self-administered, internet-based questionnaire of adults, who reported 
providing care for an adult relative with epilepsy, were included in the caregiver group. 
Propensity score methods were used to construct a 5:1 matched control group from 
the general NHWS population, excluding caregivers for any other condition, matched 
on demographics and health characteristics. The caregiver and control groups were 
compared on health status (SF-12v2 Physical Component Summary (PCS) and Mental 
Component Summary (MCS) score) and resource use (number of self-reported hospi-
talizations, ER visits, and physician visits in the past 6 months). Employed caregivers 
were similarly matched to employed controls from the general NHWS respondents 
and compared on work productivity using the Work Productivity and Activity Impair-
ment (WPAI) questionnaire. Statistical analyses included chi-square tests, t-tests, and 
generalized linear models. RESULTS: Of the 75,000 NHWS respondents, 222 self-
reported caregivers were matched to 1,110 controls (p > 0.25 for all included covari-
ates). The caregiver group was 51.8% female with mean (standard deviation) age of 
45.2 (15.4) years. Caregivers had lower mean SF-12v2 PCS scores than controls (43.0 
vs. 46.3, respectively; p < 0.0001) and showed no difference on mean MCS scores 
(44.8 vs. 46.3, respectively; p = 0.090). Caregivers reported signiﬁcantly (p < 0.0001) 
more ER visits (rate ratio (RR) = the ratio of the caregiver group mean to the control 
group mean = 4.15), hospitalizations (RR = 6.44), and provider visits (RR = 1.59) 
than controls. Employed caregivers (n = 124) reported signiﬁcantly (p ≤ 0.0018) higher 
rates of absenteeism (RR = 2.66), presenteeism (RR = 2.08), overall work impairment 
(RR = 2.02), and activity impairment (RR = 1.76) versus controls. CONCLUSIONS: 
Caregivers of adults with epilepsy reported utilizing more health care resources, and 
had lower work productivity, worse physical health status yet no difference in mental 
health status versus non-caregivers.
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IMPACT OF MEDICATION ADHERENCE TO DISEASE-MODIFYING 
DRUGS ON SEVERE RELAPSE, AND DIRECT AND INDIRECT COSTS 
AMONG EMPLOYEES WITH MULTIPLE SCLEROSIS
Ivanova JI1, Phillips AL2, Bergman RE1, Birnbaum HG3, Stewart M4, Meletiche DM2
1Analysis Group, Inc., New York, NY, USA, 2EMD Serono, Inc., Rockland, MA, USA, 
3Analysis Group, Inc., Boston, MA, USA, 4Pﬁzer Inc, New London, CT, USA
OBJECTIVES: Compare multiple sclerosis (MS) severe relapse rates and total direct 
and indirect costs over a two-year study period between employees with MS adherent 
and nonadherent to disease-modifying drugs (DMDs) METHODS: Employees with 
≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim January 1, 2002–
December 31, 2006 were selected from a large US administrative claims database. 
Patients had continuous coverage ≥6 months before (baseline) and ≥24 months after 
(study period) their index date (ﬁrst DMD claim). Adherence was measured using the 
medication possession ratio (MPR) over the 24-month study period. Patients with 
MPR ≥80% were classiﬁed as adherent (n = 448) and those with MPR < 80% were 
classiﬁed as nonadherent (n = 200). Multivariate analyses adjusting for differences in 
baseline characteristics were used to compare severe relapse rates (inpatient or emer-
gency department visit with MS diagnosis) and costs in 2007 dollars between DMD 
adherent and nonadherent patients. Direct medical costs were calculated as reimburse-
ments to providers for medical services and prescription drugs excluding DMDs. 
Indirect costs included disability and medically-related absenteeism costs. RESULTS: 
DMD adherent patients were on average older (43.5 vs. 41.8 years, P = 0.015) and 
more likely to be male (38.6% vs. 26.0%, P = 0.002) compared with nonadherent 
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patients. Adherent patients had lower rate of depression (4.7% vs. 9.5%, P = 0.019), 
higher rate of previous DMD use (49.1% vs. 40.0%, P = 0.032), and higher baseline 
MS-related costs ($4757 vs. $4037, P < 0.001). After adjusting for differences in 
baseline characteristics, DMD adherent patients had lower occurrence of severe 
relapses (12.4% vs. 19.9%, P = 0.013) and lower total (direct and indirect) costs 
($14,095 vs. $16,638, P = 0.048). CONCLUSIONS: Over the two-year study period, 
DMD adherence was associated with signiﬁcantly fewer severe relapses and lower 
total medical costs.
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PERCEIVED CAREGIVER BURDEN AND HEALTH RELATED QUALITY OF 
LIFE IN ALZHEIMER’S CAREGIVERS
Langley PC1, Wagner JS2, DiBonaventura MD3
1University of Minnesota, Minneapolis, MN, USA, 2KantarHealth, Princeton, NJ, USA, 
3KantarHealth, New York, NY, USA
OBJECTIVES: To assess the contribution of the Zarit score, a measure of perceived 
caregiver burden in Alzheimer’s disease, to health related quality of life as measured 
by the physical and mental component scores of the SF-12 instrument and SF-6D 
health utilities. METHODS: A survey of Alzheimer caregivers was undertaken in the 
US in 2009 (n = 1,079). This survey captured both the characteristics of caregivers 
and the characteristics of the patient to whom the caregiver gave most attention. At 
the same time, caregivers were asked to complete the Zarit burden of care question-
naire and the SF-12 HRQoL instrument. To assess the impact of Zarit scores on 
HRQoL, linear regression (ordinary least squares) models were speciﬁed and estimated 
for the physical and mental component summary scores of the SF-12 and the health 
utility scores from the SF-6D. Independent variables included: caregiver and patient 
characteristics. RESULTS: Average PCS and MCS scores were 47.7 (STD 11.17) and 
42.5 (STD 11.93) respectively; utility score was 0.68 (STD 0.13). Zarit scores were 
distributed with 20.4% of respondents reporting a minimal or no burden, 37.7% a 
mild to moderate burden, 33.1% moderate to severe burden and 8.8% a severe 
burden. Overall16.3% were judged to have mild AD, 53.7% moderate and 30.0% 
severe. Zarit scores played the key role with their greatest impact on the MCS rather 
than the PCS dimensions of the SF-12. In the severe AD category the PCS deﬁcit is 
−5.65 (t = −4.23) compared to a deﬁcit of −17.94 (t = −14.09) for MCS. The corre-
sponding health utility deﬁcit is −0.19 (t = −13.15). Other key variables are caregiver 
age and gender, patient age and gender and living situation. CONCLUSIONS: Per-
ceived caregiver burden is associated primarily with deﬁcits on the mental component 
scores of the SF-12 and on SF-6D health utilities.
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INTERIM ANALYSIS OF A LARGE ONGOING PHASE IV PROSPECTIVE 
OBSERVATIONAL COHORT STUDY (MDS ON BOTOX® UTILITY-
MOBILITY) OF BOTULINUM TOXIN TYPE A ON HEALTH UTILITY IN 
PATIENTS RECEIVING TREATMENT FOR APPROVED THERAPEUTIC 
INDICATIONS IN CANADA
Simonyi S1, Jog M2, Beauchamp R3, Miller R4, Bhogal M1, Wein T5
1Allergan Inc., Markham, ON, Canada, 2London Health Sciences Centre, London, ON, 
Canada, 3Children’s & Women’s Health Centre of B.C, Vancouver, ON, Canada, 4Dalhousie 
University, Halifax, NS, Canada, 5McGill University, Montreal, QC, Canada
OBJECTIVES: Botulinum Toxin Type-A (BoNTA) is approved for many therapeutic 
indications in Canada, including blepharospasm, 7th cranial nerve disorders, cervical 
dystonia, focal spasticity, cerebral palsy, and hyperhidrosis. Unfortunately, little is 
known about the impact of treatment on health utility. The objective of the ongoing 
national MOBILITY study is to measure the impact of BoNTA on health utility. 
METHODS: Phase IV prospective observational cohort study in patients receiving 
BoNTA for approved therapeutic indications in Canada. Physical component scores 
(PCS), and mental component scores (MCS) are derived from self-reported SF-12v2 
at baseline, week 4 and subsequent clinic visits. Health utility is then measured using 
the SF-6D scoring programme. In this interim analysis continuous data were analyzed 
by student’s t-test and dichotomous data by Chi-square test. RESULTS: To date 917 
patients have been enrolled at 40 clinical sites with a 94.5% retention rate. 69.7% of 
patients returned the week 4 survey and data from 608 individuals were included in 
the analysis (526 were receiving ongoing BOTOX® treatment at baseline; 82 were 
BoNTA-naïve). Signiﬁcant differences were detected in self-reported SF-6D scores 
between baseline and week 4 in the analysis of continuous (p = 0.05) and dichotomized 
data (p = 0.0001), and between baseline and week 4 in the analysis of continuous 
MCS data (p = 0.03). Among BoNTA-naïve patients, there was a statistically signiﬁ-
cant difference in SF-6D scores between baseline and week 4 (p = 0.03 for continuous 
data; p = 0.018 for dichotomized data). There were no statistical signiﬁcant changes 
in the SF-6D scores for patients receiving on-going treatment. CONCLUSIONS: This 
interim analysis from a large ongoing national study shows that signiﬁcant improve-
ments in health utility are obtained in patients receiving BoNTA for therapeutic indica-
tions. Health utility beneﬁt was most pronounced in BoNTA-naive patients as 
evidenced by week 4 MCS scores (the expected peak effect window). Further recruit-
ment and long term follow-up and analyses are ongoing.
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MAPPING FROM DISEASE-SPECIFIC MEASURES TO HEALTH-STATE 
UTILITY VALUES IN CHRONIC MIGRAINEURS
Gillard PJ1, Devine B1, Varon SF2, Maglinte GA2, Sullivan S1
1University of Washington, Department of Pharmacy, Seattle, WA, USA, 2Allergan, Inc, 
Irvine, CA, USA
OBJECTIVES: To develop algorithms that convert disease-speciﬁc quality-of-life 
scores for the Headache Impact Test (HIT)-6 and the Migraine Speciﬁc Quality of 
Life, v. 2.1 (MSQ) Questionnaire to health-state utility values derived from the 
EuroQoL-5D (EQ-5D) in chronic migraineurs. METHODS: Data from a cross-sec-
tional multi-country study was used. Chronic migraineurs (ICHD-2 diagnosis of 
migraine and ≥15 headache days/month) completed a series of questions including the 
HIT-6 (n = 547), MSQ (n = 499), and EQ-5D. Subjects were randomly assigned to 
training and validation samples of equal size. Correlations between paired EQ-5D 
index scores and both HIT-6 scores and MSQ domain scores (Role-Restrictive [RR], 
Role-Preventative [RP], and Emotional-Function [EF]) were examined using Spearman 
correlation coefﬁcients. Regression models were constructed to predict EQ-5D utility 
values from the HIT-6 scores or the MSQ domain scores. Preferred algorithms were 
validated using the validation samples. RESULTS: Correlations between the EQ-5D 
index score and the HIT-6 and MSQ dimension scores were statistically signiﬁcant (p 
< 0.001) with correlation coefﬁcients of −0.33 (HIT-6), 0.44 (MSQ-RR), 0.46 (MSQ-
RP), and 0.30 (MSQ-EF). The preferred HIT-6 algorithm was a non-linear model 
which contained a quadratic term for HIT-6, and explained 34% of the variance in 
the training sample. The preferred MSQ algorithm was a linear model with covariates 
representing each domain, and explained 43% of the variance in the training sample. 
Both models also included covariates for age, gender, employment status, headache 
medication use, and comorbidities. In the validation analyses, no statistically signiﬁ-
cant difference was observed between the mean observed EQ-5D score and the mean 
EQ-5D score estimated using the preferred algorithms. CONCLUSIONS: The relation-
ship between the two disease-speciﬁc instruments and the EQ-5D are sufﬁciently 
robust to use regression equations to estimate EQ-5D utility values. These preferred 
models may be useful in estimating health-state utilities in trials of CM patients where 
no preference-based measure is present.
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CONCORDANCE OF SELF-REPORT MEASURES OF DSM-IV-TR, ICD-10, 
AND RDC INSOMNIA WITH STANDARDIZED CLINICAL ASSESSMENTS 
IN THE AMERICA INSOMNIA SURVEY (AIS)
Kessler RC1, Coulouvrat C2, Lakoma MD1, Hajak G3, Roth T4, Sampson N1, Shahly V1, 
Shillington AC5, Stephenson JJ6, Walsh J7, Zammit G8
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of Regensburg, Regensburg, Germany, 4Henry Ford Hospital, Detroit, MI, USA, 5EPI-Q Inc, 
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OBJECTIVES: To evaluate the reliability and validity of the Brief Insomnia Question-
naire (BIQ), a fully-structured measure to assess insomnia based on DSM-IV-TR, 
ICD-10, and RDC criteria. METHODS: The AIS is a large (n = 10,094) epidemiologi-
cal survey of the prevalence and correlates of insomnia in a nationally representative 
sample of managed health care plan subscribers. Probability sub-samples of AIS 
respondents over-sampling BIQ cases completed either short-term test-retest interviews 
(n = 59) or clinical reappraisal interviews (n = 203) to assess BIQ reliability and 
validity. RESULTS: Test-retest correlations were .72–.95 for reports of frequency and 
.47–.94 for reports of severity of sleep problems (initiation, maintenance, non-restor-
ative sleep), .66–.88 for reports of daytime impairment/distress, and .62 for reported 
duration. Good individual-level concordance was found between diagnoses based on 
the BIQ and clinical interviews for meeting criteria in any of the three diagnostic 
systems, with area under the receiver operating characteristic curve (AUC, a measure 
of classiﬁcation accuracy not inﬂuenced by disorder prevalence) of .86 for dichoto-
mous classiﬁcations. AUC increased to .94 when symptom-level data were added to 
generate a continuous measure of predicted probability of clinical diagnosis. AUC was 
lower for dichotomous classiﬁcations based on RDC (.68) and ICD-10 (.70) than 
DSM-IV-TR (.83) criteria, but increased when symptom-level data were added to 
generate continuous measures of predicted probability of diagnoses (.92–.95). CON-
CLUSIONS: The results demonstrate that the BIQ can be used to obtain accurate 
estimates of prevalence and correlates of insomnia in the American Insomnia Survey.
PND24
EVALUATING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON 
NEXT DAY FUNCTIONING
Abraham L1, Lasch KE2, Patrick J3, Piault E2, Tully SE2, Treglia M4
1Pﬁzer Ltd, Sandwich, UK, 2Mapi Values, Boston, MA, USA, 3Pﬁzer, Inc., New London, CT, 
USA, 4Pﬁzer Inc, New London, CT, USA
OBJECTIVES: Symptoms of Restless Legs Syndrome (RLS) typically worsen in the 
early evening and nighttime affecting patients’ quality and duration of sleep which 
can have next day sequelae detrimental to daytime performance. The present qualita-
tive research aimed to support the content validity of a new self-reported outcome 
measure to document the impact of disturbed sleep due to RLS on next day function-
ing. METHODS: An initial conceptual framework was developed based upon a review 
of the literature. The development of the Restless Legs Syndrome—Next Day Impact 
(RLS-NDI) questionnaire included: concept elicitation interviews with 20 clinician-
conﬁrmed idiopathic RLS patients in the US (aged 35–64); grounded theory data 
collection and analysis methods; achievement of saturation; and review by clinical and 
